AI blood test could spare some breast cancer patients extra chemo

NCT ID NCT04874064

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop a blood test that uses artificial intelligence to analyze tumor material in the blood of people with triple negative breast cancer. The goal is to better predict which patients need more chemotherapy after surgery and which can safely avoid it. Researchers will collect blood and tissue samples from 130 participants to build a test that guides treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, H3T 1E1, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • St. Joseph's Health Care London

    RECRUITING

    London, Ontario, N6A 4V2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Ottawa Hospital Cancer Center

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact